GLP-1 drugs to reduce metabolic risk in Duchenne muscular dystrophy
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether a diabetes medication called a GLP-1 receptor agonist (semaglutide) can help people with Duchenne muscular dystrophy manage weight and reduce metabolic complications like high blood pressure and high cholesterol. The medication may help protect heart and metabolic health in this population.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and at least 18 years old
- You have a BMI (body mass index) of 30 or higher, OR a BMI of 27+ with a weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol
- You have been diagnosed with Duchenne muscular dystrophy (confirmed by muscle biopsy or genetic test)
- You do not have type 1 diabetes, uncontrolled type 2 diabetes, or take insulin or certain diabetes pills
- You have no history of pancreatitis (pancreas inflammation) or thyroid cancer in your family
- You are able to undergo MRI scans and tolerate study procedures safely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This study tests whether taking HMB and vitamin D can help older adults with type 2 diabetes keep their muscle mass while they start taking semaglutide for weight loss. It may help prevent muscle loss during weight management.
This trial studies how a weight-loss medicine (Semaglutide) may affect energy use in the heart of people with pulmonary arterial hypertension (high blood pressure in the lungs). It uses a special MRI to measure heart function before and after treatment.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.